Search | Clinical Trials Finder

Conditions: Parkinson's Disease
Interventions: Mesenchymal Stem Cells, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 50 Years to 79 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Systemic Lupus Erythematosus
Interventions: Low Dose Mesenchymal Stem Cells (MSCs), High Dose Mesenchymal Stem Cells (MSCs), Placebo Infusion; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • Atlanta, Georgia + 6 more

Conditions: Multisystem Inflammatory Syndrome in Children
Interventions: Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs); Biological
Lead sponsor: Joanne Kurtzberg, MD; Other
Eligibility: 18 Years to 20 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Atlanta, Georgia • Westchester, New York • Durham, North Carolina

Conditions: COVID-19 Pneumonia, Viral Pneumonia
Interventions: Allogeneic Mesenchymal Stromal Cells; Biological
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Autism Spectrum Disorder, Autism, ASD, Autism Spectrum Disorder (ASD)
Interventions: Umbilical Cord Blood-Derived Stem Cells and Exosomes, Glutathione; Biological · Drug
Lead sponsor: Adia Med of Winter Park LLC; Other
Eligibility: 3 Years to 12 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Winter Park, Florida • Green Bay, Wisconsin

Conditions: COVID, Corona Virus Infection, COVID19
Interventions: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University., Placebo; Biological · Other
Lead sponsor: Joanne Kurtzberg, MD; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Boca Raton, Florida • Miami, Florida • Valhalla, New York + 1 more

Conditions: Mesenchymal Stromal Cells, Remestemcel-L, Acute Respiratory Distress Syndrome, COVID
Interventions: Remestemcel-L, Placebo; Biological · Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 21
States / cities: Gilbert, Arizona • Los Angeles, California • Stanford, California + 16 more

Conditions: Diabetes Mellitus, Ischemic Heart Disease
Interventions: 100 million Allogeneic Mesenchymal Human Stem Cells, Placebo; Drug · Other
Lead sponsor: Joshua M Hare; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Stroke, Stroke, Ischemic
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: Not listed
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Rheumatoid Arthritis
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Pasadena, Texas

Conditions: Ischemic Heart Disease
Interventions: umbilical cord-derived mesenchymal stromal cells (UC-MSCs); Biological
Lead sponsor: Roberto Bolli; Other
Eligibility: 21 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Miami, Florida • Louisville, Kentucky • Houston, Texas

Conditions: Alcoholic Liver Cirrhosis
Interventions: Cellgram™ (Bone marrow-derived MSCs); Biological
Lead sponsor: Pharmicell Co., Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: PARKINSON DISEASE (Disorder), Atypical Parkinsonism
Interventions: Autologous Bone Marrow Aspirate (BMA) and Bone Marrow Aspirate Concentrate (BMAC); Biological
Lead sponsor: Apeiron Research Center; Other
Eligibility: 40 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Multiple System Atrophy
Interventions: HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 18 Years to 85 Years
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Type 1 Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Insulin-Dependent, Juvenile Diabetes
Interventions: PROCHYMAL®, Placebo; Drug
Lead sponsor: Mesoblast, Inc.; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 20
States / cities: Birmingham, Alabama • La Jolla, California • Stanford, California + 17 more

Conditions: Cardiomyopathy, Heart Failure
Interventions: Laboratory Biomarker Analysis, Standard of Care, Mesenchymal Stem Cell Transplantation; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Frailty
Interventions: Mesenchymal Stem Cells (MSCs); Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 65 Years to 85 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Grade B aGVHD, Grade C aGVHD, Grade D aGVHD
Interventions: remestemcel-L; Drug
Lead sponsor: Mesoblast, Inc.; Industry
Eligibility: 2 Months to 17 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 20
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 15 more

Conditions: Endothelial Dysfunction, Metabolic Syndrome, Chronic Inflammation
Interventions: UCMSCs, BMMSCs, Placebo; Biological · Other
Lead sponsor: Joshua M Hare; Other
Eligibility: 21 Years to 95 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Epidermolysis Bullosa
Interventions: Thymoglobulin, Cyclophosphamide, Fludarabine, Total Body Irradiation, Bone marrow infusion, Tacrolimus, Mycophenolate Mofetil, Donor mesenchymal stem cell infusions, Busulfan; Drug · Radiation · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 25 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Sars-CoV2, Acute Respiratory Distress Syndrome, COVID-19
Interventions: Mesenchymal Stromal Cells, Supportive Care; Biological · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cerebral Palsy
Interventions: Infusion of allogeneic umbilical cord blood, Infusion of MSCs; Biological
Lead sponsor: Joanne Kurtzberg, MD; Other
Eligibility: 24 Months to 60 Months
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cerebral Palsy
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 3 Years and older · Male only
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions: Best Practice, Mesenchymal Stem Cell; Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease

Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)

Infusions of Mesenchymal Stromal Cells in Children With Multisystem Inflammatory Syndrome

Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias

Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study

hCT-MSCs for COVID19 ARDS

MSCs in COVID-19 ARDS

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

Individual Patient Expanded Access IND for the Treatment of Stroke

Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis

Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy

Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC

Autologous Bone Marrow Aspirate (IV) and Bone Marrow Concentrate (Intranasal) for Parkinson's Disease and Parkinson-Plus Syndromes (SPARC-PD)

"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."

PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)

Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines

Mesenchymal Stem Cells for Age-Related Frailty

A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)

Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.

MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs

Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)

A Study of UCB and MSCs in Children With CP: ACCeNT-CP

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy

Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia